Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, explains the impact of lag time between a drug's approval and its availability for use in the electronic medical record (EMR).
Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, explains the impact of lag time between a drug's approval and its availability for use in the electronic medical record (EMR).
Transcript
How can the lag time between a drug’s approval and the availability of the drug in the electronic health record for a physician to order impact patient care?
That’s something you could imagine: if there is a significant delay between a new regimen, and the only way to use a new regimen is through the EMR, those patients are not going to be treated with that new regimen. That was really the impetus for us to look at our own data and see how long that took because although we have not measured it, that’s something certainly something we could look at, which is what would happen, what is the advantage of getting new treatments in, assuming the new treatments are better treatments, which is the case. Obviously, the sooner you get the new treatment in the better chance you have on having an impact on patient care. So, it would be nice to look at that ourselves, and I think that might be something hopefully we will present at the next ISPOR.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More